Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Joe Copia who wrote (91655)	9/12/2001 2:06:45 PM
From: InOverMyHead	Read Replies (1) \| Respond to of 150070

What nationality are you Joe? I would hate for our country to resort to those measures. We know the people responsible for this terroristic event. Those are the people who need to be dealt with. Just because other people are of the same nationality as the terrorists doesn't give the U.S. the right to label all Arabs as a potential terroristic threat.

To: Joe Copia who wrote (91655)	9/12/2001 2:39:39 PM
From: CIMA	Respond to of 150070

Joe, you're kidding right? Fine way for the United States, as leader of the "free world", to react. Let's take away the rights and freedoms of a particular race because they look the same as the guys who might have attacked us. Wednesday September 12 1:35 PM ET Daily Aspirin Substantially Cuts Death Risk: Study NEW YORK (Reuters Health) - Daily aspirin use cuts the risk of death from any cause by more than one-third, a new study by Cleveland Clinic Foundation researchers has found. Senior author Dr. Michael S. Lauer and his colleagues compared mortality in a group of 1,351 aspirin users and 1,351 non-aspirin users. Their findings are published in the September 12th issue of The Journal of the American Medical Association (news - web sites). All patients included in the analysis were recruited from a group of patients who had been referred to the Cleveland Clinic for stress testing. The average age of the aspirin users was 62 compared to 56 for non-aspirin users. ``These patients are in all respects the same with the sole difference being aspirin use,'' Lauer told Reuters Health. The investigators followed the patients for an average of 3.1 years. During follow-up, 153 (or 6%) of the patients died. Aspirin users had a 4% risk of death, while the mortality risk among non-users was 8%. The three strongest factors correlating with benefit from aspirin were age, impaired exercise capacity, and a known history of heart disease. The finding that aspirin is especially beneficial in patients who are out-of-shape is ``a real take home message for physicians,'' Lauer said. He explained that he and other cardiologists are often frustrated by patients who ``perform poorly on a stress test. Everyone asks, what do we do with this patient?'' Until now, the only approach has been to promote lifestyle changes aimed at improving conditioning. ``But it is difficult to get patients to exercise,'' he said. ``Now, we actually have a treatment for the out-of-condition patient. We can tell the patient to take an aspirin,'' Lauer added. ``That won't get them in shape, but it may save their lives.'' American Heart Association (news - web sites) President Dr. David Faxon said the findings were ``solid,'' and the result on physical condition and aspirin use was particularly powerful. In an editorial accompanying the study, Drs. Martha J. Radford and JoAnne M. Foody of Yale New Haven Health System in Connecticut, write that findings like those in this study, which are based on sophisticated analytical techniques, make a convincing case for expanding aspirin use to unstudied groups. Making clinical decisions based on these findings ``helps to guarantee that as many patients as possible are considered for effective therapies,'' they conclude. SOURCE: The Journal of the American Medical Association 2001;286:1187-